Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninety-nine patients with high-risk neuroblastoma recei...

Full description

Saved in:
Bibliographic Details
Published in:Front Pediatr
Main Authors: Cicek, Filiz, Troschke-Meurer, Sascha, Ceylan, Kiraz, Jahns, Luciana J., Zumpe, Maxi, Siebert, Nikolai, Ehlert, Karoline, Lode, Holger N.
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020
Subjects:
Pediatrics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7772209/
https://ncbi.nlm.nih.gov/pubmed/33392114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fped.2020.582820
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items